Detalles de la búsqueda
1.
The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations.
Future Oncol
; 20(16): 1099-1110, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38258557
2.
Estimating the US Baseline Distribution of Health Inequalities Across Race, Ethnicity, and Geography for Equity-Informative Cost-Effectiveness Analysis.
Value Health
; 26(10): 1485-1493, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37414278
3.
Distributional Cost-Effectiveness Analysis of Health Technologies: Data Requirements and Challenges.
Value Health
; 26(1): 60-63, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35941004
4.
The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis.
Value Health
; 26(2): 216-225, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36192293
5.
Assessing the impact of grief on quality of life, work productivity, and health outcomes for parents bereaved from SMA: A study protocol.
Cost Eff Resour Alloc
; 21(1): 55, 2023 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-37612702
6.
A Pragmatic Guide to Assessing Real Option Value for Medical Technologies.
Value Health
; 2022 Jun 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35752536
7.
Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom.
Diabetes Obes Metab
; 21(4): 1010-1017, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30565386
8.
The current and projected economic burden of Parkinson's disease in the United States.
Mov Disord
; 28(3): 311-8, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23436720
9.
The Value of New: Consideration of Product Novelty in Health Technology Assessments of Pharmaceuticals.
Appl Health Econ Health Policy
; 21(2): 305-314, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36529826
10.
Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer.
Pharmacoeconomics
; 40(6): 623-631, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35527331
11.
When are breakthrough therapies cost-effective?
J Manag Care Spec Pharm
; 28(7): 732-739, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35737862
12.
Evaluating Real-World National and Regional Trends in Definitive Closure in U.S. Burn Care: A Survey of U.S. Burn Centers.
J Burn Care Res
; 43(1): 141-148, 2022 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34329478
13.
Stakeholder point of view on prescription drug affordability - a systematic literature review and content analysis.
Health Policy
; 125(9): 1158-1165, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34281700
14.
Cost-effectiveness of intensification with SGLT2 inhibitors for type 2 diabetes.
Am J Manag Care
; 27(8): e269-e277, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34460181
15.
A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States.
Adv Ther
; 38(4): 1811-1831, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33650025
16.
Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin.
Pharmacoeconomics
; 39(3): 317-330, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33150566
17.
Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies.
Appl Health Econ Health Policy
; 19(5): 625-634, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34028672
18.
The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications.
Value Health
; 13(6): 685-94, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20825627
19.
Relationship Between Patient Characteristics and Number of Procedures as well as Length of Stay for Patients Surviving Severe Burn Injuries: Analysis of the American Burn Association National Burn Repository.
J Burn Care Res
; 41(5): 1037-1044, 2020 09 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-32221517
20.
A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA.
Pharmacoeconomics
; 38(1): 39-56, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31452079